

Acute Migraine Drugs Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment (Preventive, Pain Relieving), By Route of Administration (Oral, Injectable, Nasal Sprays, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2020-2030F

<https://marketpublishers.com/r/AAD29E050256EN.html>

Date: February 2025

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: AAD29E050256EN

Abstracts

The global Acute Migraine Drugs Market was valued at USD 2.35 billion in 2024 and is projected to experience consistent growth during the forecast period, with a compound annual growth rate (CAGR) of 4.80% through 2030. This market represents a critical segment within the pharmaceutical industry, focusing on addressing the immediate medical needs of individuals suffering from migraines—a debilitating neurological disorder characterized by severe headaches, often accompanied by nausea, vomiting, and light sensitivity. It includes a range of pharmaceutical solutions designed to alleviate symptoms during migraine episodes and reduce their recurrence.

Key Market Drivers:

1. **Increasing Global Prevalence of Migraine:** The rising global prevalence of migraine is a major driver of growth in the Global Acute Migraine Drugs Market. Between 1990 and 2021, the global migraine burden increased significantly, with prevalence rising by 58.15%, from 732.56 million to 1.16 billion cases. The incidence rate also climbed by 42.06%, signaling a notable surge in newly diagnosed cases. Furthermore, Disability-Adjusted Life Years (DALYs) linked to migraines increased by 58.27%, highlighting the growing health and economic burden of the condition worldwide. This surge points to an expanding market opportunity for acute migraine treatments as pharmaceutical

companies and healthcare providers address the increasing demand for effective solutions. As the number of migraine sufferers grows, the demand for fast-acting and specialized treatments rises correspondingly. Migraines are among the most common neurological disorders, affecting millions globally, and are recognized as one of the leading causes of disability, according to health organizations such as the World Health Organization (WHO) and the Global Burden of Disease Study. The rising number of patients seeking treatment is directly contributing to the expanding market for acute migraine drugs, with both prescription and over-the-counter (OTC) medications seeing increased sales and revenue potential. The growing prevalence is not limited to specific demographics, as it spans across various age groups and regions, offering new opportunities for pharmaceutical companies.

Key Market Challenges:

1. **Regulatory Barriers and Stringent Approval Processes:** Regulatory approvals are essential for ensuring patient safety but can also present challenges in the development and commercialization of new migraine drugs. Regulatory agencies like the FDA and EMA impose strict criteria, requiring extensive clinical trials, meticulous data collection, and significant time and resource investment. The extended approval timelines can delay the market introduction of innovative migraine treatments, limiting patient access to potentially improved options and impacting pharmaceutical companies' revenue streams. To address this, companies must adopt proactive engagement strategies with regulatory bodies, such as early communication, well-designed clinical trials, and thorough data collection efforts to expedite the approval process.

Key Market Trends:

1. **Personalized Medicine and Targeted Therapies:** Personalized medicine is transforming the migraine treatment landscape by tailoring therapies to individual patient profiles, taking into account genetic, lifestyle, and clinical factors. Targeted therapies address the underlying mechanisms of migraine attacks, improving treatment efficacy and minimizing adverse effects, thereby enhancing patient outcomes. This trend meets growing patient demand for more effective solutions and drives innovation and market expansion. Pharmaceutical companies are investing in research to identify biomarkers and genetic factors linked to migraine susceptibility, leading to the development of drugs with precise mechanisms of action that offer personalized treatment options for patients.

Key Market Players:

Endo International PLC

AbbVie Inc.

Impax Laboratories LLC

GlaxoSmithKline PLC

Astellas Pharma Inc.

Amgen Inc.

Bayer AG

AstraZeneca PLC

Dr. Reddy's Laboratories Ltd

Eli Lilly and Company

Pfizer Inc.

Report Scope: The Global Acute Migraine Drugs Market has been segmented as follows, along with detailed industry trends:

By Treatment:

Preventive

Pain Relieving

By Route of Administration:

Oral

Injectable

Nasal Sprays

Other

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America (United States, Canada, Mexico)

Europe (France, United Kingdom, Italy, Germany, Spain)

Asia-Pacific (China, India, Japan, Australia, South Korea)

South America (Brazil, Argentina, Colombia)

Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape: In-depth analysis of major companies within the Global Acute Migraine Drugs Market.

Customization Options Available: TechSci Research offers tailored solutions for the Global Acute Migraine Drugs market report based on specific company needs.

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. ACUTE MIGRAINE DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Treatment (Preventive, Pain Relieving)
 - 5.2.2. By Route of Administration (Oral, Injectable, Nasal Sprays, Others)
 - 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map

6. NORTH AMERICA ACUTE MIGRAINE DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Treatment
 - 6.2.2. By Route of Administration
 - 6.2.3. By Distribution Channel
 - 6.2.4. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Acute Migraine Drugs Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Treatment
 - 6.3.1.2.2. By Route of Administration
 - 6.3.1.2.3. By Distribution Channel
 - 6.3.2. Canada Acute Migraine Drugs Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Treatment
 - 6.3.2.2.2. By Route of Administration
 - 6.3.2.2.3. By Distribution Channel
 - 6.3.3. Mexico Acute Migraine Drugs Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Treatment
 - 6.3.3.2.2. By Route of Administration
 - 6.3.3.2.3. By Distribution Channel

7. EUROPE ACUTE MIGRAINE DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast

- 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Treatment
 - 7.2.2. By Route of Administration
 - 7.2.3. By Distribution Channel
 - 7.2.4. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. Germany Acute Migraine Drugs Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Treatment
 - 7.3.1.2.2. By Route of Administration
 - 7.3.1.2.3. By Distribution Channel
 - 7.3.2. United Kingdom Acute Migraine Drugs Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Treatment
 - 7.3.2.2.2. By Route of Administration
 - 7.3.2.2.3. By Distribution Channel
 - 7.3.3. Italy Acute Migraine Drugs Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecasty
 - 7.3.3.2.1. By Treatment
 - 7.3.3.2.2. By Route of Administration
 - 7.3.3.2.3. By Distribution Channel
 - 7.3.4. France Acute Migraine Drugs Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Treatment
 - 7.3.4.2.2. By Route of Administration
 - 7.3.4.2.3. By Distribution Channel
 - 7.3.5. Spain Acute Migraine Drugs Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast

- 7.3.5.2.1. By Treatment
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Distribution Channel

8. ASIA-PACIFIC ACUTE MIGRAINE DRUGS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Treatment
 - 8.2.2. By Route of Administration
 - 8.2.3. By Distribution Channel
 - 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Acute Migraine Drugs Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Treatment
 - 8.3.1.2.2. By Route of Administration
 - 8.3.1.2.3. By Distribution Channel
 - 8.3.2. India Acute Migraine Drugs Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Treatment
 - 8.3.2.2.2. By Route of Administration
 - 8.3.2.2.3. By Distribution Channel
 - 8.3.3. Japan Acute Migraine Drugs Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Treatment
 - 8.3.3.2.2. By Route of Administration
 - 8.3.3.2.3. By Distribution Channel
 - 8.3.4. South Korea Acute Migraine Drugs Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast

- 8.3.4.2.1. By Treatment
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Acute Migraine Drugs Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Treatment
 - 8.3.5.2.2. By Route of Administration
 - 8.3.5.2.3. By Distribution Channel

9. SOUTH AMERICA ACUTE MIGRAINE DRUGS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Treatment
 - 9.2.2. By Route of Administration
 - 9.2.3. By Distribution Channel
 - 9.2.4. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Acute Migraine Drugs Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Treatment
 - 9.3.1.2.2. By Route of Administration
 - 9.3.1.2.3. By Distribution Channel
 - 9.3.2. Argentina Acute Migraine Drugs Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Treatment
 - 9.3.2.2.2. By Route of Administration
 - 9.3.2.2.3. By Distribution Channel
 - 9.3.3. Colombia Acute Migraine Drugs Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast

- 9.3.3.2.1. By Treatment
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Distribution Channel

10. MIDDLE EAST AND AFRICA ACUTE MIGRAINE DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Treatment
 - 10.2.2. By Route of Administration
 - 10.2.3. By Distribution Channel
 - 10.2.4. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Acute Migraine Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Treatment
 - 10.3.1.2.2. By Route of Administration
 - 10.3.1.2.3. By Distribution Channel
 - 10.3.2. Saudi Arabia Acute Migraine Drugs Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Treatment
 - 10.3.2.2.2. By Route of Administration
 - 10.3.2.2.3. By Distribution Channel
 - 10.3.3. UAE Acute Migraine Drugs Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Treatment
 - 10.3.3.2.2. By Route of Administration
 - 10.3.3.2.3. By Distribution Channel

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Recent Developments

12.2. Product Launches

12.3. Mergers & Acquisitions

13. GLOBAL ACUTE MIGRAINE DRUGS MARKET: SWOT ANALYSIS

14. COMPETITIVE LANDSCAPE

14.1. Endo International PLC

14.1.1. Business Overview

14.1.2. Product & Service Offerings

14.1.3. Recent Developments

14.1.4. Financials (If Listed)

14.1.5. Key Personnel

14.1.6. SWOT Analysis

14.2. AbbVie Inc.

14.3. Impax Laboratories LLC

14.4. Glaxo Smith Kline PLC

14.5. Astellas Pharma Inc

14.6. Amgen Inc

14.7. Bayer AG

14.8. AstraZeneca PLC

14.9. Dr. Reddy's Laboratories Ltd

14.10. Eli Lilly and Company

14.11. Pfizer Inc

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Acute Migraine Drugs Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment (Preventive, Pain Relieving), By Route of Administration (Oral, Injectable, Nasal Sprays, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/AAD29E050256EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AAD29E050256EN.html>